GCGR and metabolic dysfunction-associated steatohepatitis: Survodutide, a novel GLP-1/glucagon receptor co-agonist, is currently undergoing clinical evaluation for its therapeutic potential in metabolic dysfunction-associated steatohepatitis (MASH).